Immix Biopharma (IMMX) Other Non-Current Liabilities (2020 - 2021)
Quarterly results put Other Non-Current Liabilities at $23.4 million for Q4 2021, up 3972.14% from a year ago — trailing twelve months through Dec 2021 was $23.4 million (up 3972.14% YoY), and the annual figure for FY2021 was $23.4 million, up 3972.14%.
Immix Biopharma has reported Other Non-Current Liabilities over the past 2 years, most recently at $23.4 million for Q4 2021.
- Other Non-Current Liabilities reached $23.4 million in Q4 2021 per IMMX's latest filing, up from $575000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $23.4 million in Q4 2021 and bottomed at $575000.0 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 23.41 Mn |
| Dec 31, 2020 | 575,000.00 |